Medullary thyroid cancer in the era of tyrosine kinase inhibitors: To treat or not to treat - and with which drug - those are the questions

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 12, 2014, Pages 4390-4396

  Cabanillas, Maria E ^a   Hu, Mimi I ^a   Jimenez, Camilo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CABOZANTINIB; PLACEBO; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; THYROTROPIN; VANDETANIB; ANILIDE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BONE METASTASIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER PROGNOSIS; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG USE; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; DYSPHONIA; ECHOGRAPHY; ELECTROCARDIOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FINE NEEDLE ASPIRATION BIOPSY; FISTULA; GENE MUTATION; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEART FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL HISTORY; NAUSEA; NEUTROPENIA; ONCOGENE RET; PERFORATION; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PHYSICAL EXAMINATION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TORSADE DES POINTES; TUMOR VOLUME; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; THYROID NEOPLASMS;

ANILIDES; CARCINOMA, NEUROENDOCRINE; DNA MUTATIONAL ANALYSIS; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; QUINAZOLINES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84916600672     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2811     Document Type: Article

References (20)

1. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134-2142.
2. Boostrom SY, Grant CS, Thompson GB, et al. Need for a revised staging consensus in medullary thyroid carcinoma. Arch Surg. 2009; 144:663-669.
3. Meijer JA, le Cessie S, van den Hout WB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2010;72:534-542.
4. Calcitonin and carcinoembryonic antigen (CEA) doubling time calculator. American Thyroid Association. http://www.thyroid.org/thyroid-physicians-professionals/calculators/thyroid-cancercarcinoma. Accessed August 11, 2014.
5. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029-2034.
6. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012;167:643-650.
7. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010;95:2588-2595.
8. Fromigué J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91: 2496-2499.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
10. Tuttle RM, Haddad R, Ball DW, et al. NCCN clinical practice guidelines in oncology: thyroid carcinoma. J Natl Compr Canc Netw. 2014;1.2014.
11. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30: 134-141.
12. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639-3646.
13. Sherman SI, Cohen EE, Schoffski P, et al. Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. In: Proceedings from the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, IL. Abstract 6000.
14. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004;23:6056-6063.
15. Caprelsa (vandetanib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2013.
16. Cometriq (cabozantinib) [package insert]. South San Francisco, CA: Exelixis Pharmaceuticals Inc; 2012.
17. Baudry C, Paepegaey AC, Groussin L. Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med. 2013;369:584-586.
18. Nella AA, Lodish MB, Fox E, et al. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient. J Clin Endocrinol Metab. 2014:99:3055-3059.
19. Carhill AA, Cabanillas ME, Jimenez C, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98:31-42.
20. Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab. 2013;98:2401-2408.